These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 33274491)

  • 1. Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease.
    Chrétien B; Jourdan JP; Davis A; Fedrizzi S; Bureau R; Sassier M; Rochais C; Alexandre J; Lelong-Boulouard V; Dolladille C; Dallemagne P
    Br J Clin Pharmacol; 2021 Jul; 87(7):2830-2837. PubMed ID: 33274491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis.
    Liu Y; Liu Y; Fan R; Kehriman N; Zhang X; Zhao B; Huang L
    Eur J Med Res; 2023 Feb; 28(1):95. PubMed ID: 36829251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database.
    Sato K; Mano T; Iwata A; Toda T
    J Alzheimers Dis; 2021; 82(3):1333-1344. PubMed ID: 34151816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®).
    Batteux B; Bennis Y; Bodeau S; Masmoudi K; Hurtel-Lemaire AS; Kamel S; Gras-Champel V; Liabeuf S
    Bone; 2021 Dec; 153():116137. PubMed ID: 34343739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
    Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
    Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.
    Gudin B; Ladhari C; Robin P; Laroche ML; Babai S; Hillaire-Buys D; Faillie JL
    Therapie; 2020; 75(6):641-647. PubMed ID: 32418731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
    Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
    Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis.
    Hlavaty A; Roustit M; Montani D; Chaumais MC; Guignabert C; Humbert M; Cracowski JL; Khouri C
    Br J Clin Pharmacol; 2022 Dec; 88(12):5227-5237. PubMed ID: 35679331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase
    Linselle M; Sommet A; Bondon-Guitton E; Moulis F; Durrieu G; Benevent J; Rousseau V; Chebane L; Bagheri H; Montastruc F; Montastruc JL
    Fundam Clin Pharmacol; 2017 Jun; 31(3):359-366. PubMed ID: 28036099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.
    Zhang M; Schmitt-Ulms G; Sato C; Xi Z; Zhang Y; Zhou Y; St George-Hyslop P; Rogaeva E
    PLoS One; 2016; 11(12):e0168812. PubMed ID: 28005991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Profile of Sclerosing Agents: An Analysis From the World Health Organization Pharmacovigilance Database VigiBase.
    Roselli A; Khouri C; Roustit M; Blaise S; Cracowski JL
    Dermatol Surg; 2019 Dec; 45(12):1517-1528. PubMed ID: 30829775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thirst and drugs: A study in the World Health Organization's pharmacovigilance database.
    Montastruc JL
    Br J Clin Pharmacol; 2024 Jun; 90(6):1525-1528. PubMed ID: 38627211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database.
    Chen X; Wei L; Chi L; Guo X; Chen C; Guo Z; Liang J; Zheng Y; He J; Ye X
    Br J Clin Pharmacol; 2022 May; 88(5):2180-2189. PubMed ID: 34786743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
    Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
    Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.
    Fernandez S; Lenoir C; Samer C; Rollason V
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00647. PubMed ID: 32881416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase.
    Perino J; Mottal N; Bohbot Y; Servant V; Berroneau A; Poustis P; Fenaux P; Laribi K; Charbonnier A; Bilion E; Calmettes C; Bégaud B; Pigneux A; Milpied N; Miremont-Salamé G; Théophile H; Dimicoli-Salazar S
    Br J Clin Pharmacol; 2020 May; 86(5):991-998. PubMed ID: 31912911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
    Khouri C; Lepelley M; Roustit M; Montastruc F; Humbert M; Cracowski JL
    Chest; 2018 Jul; 154(1):136-147. PubMed ID: 29275134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.